Management of Chest Pain: Clopidogrel and Lovenox in Workup

Initial Assessment and Risk Stratification

Patients presenting with chest pain should undergo immediate ECG assessment to differentiate between ST-elevation and non-ST-elevation presentations 2
Laboratory assessments should include cardiac troponin measurements to detect myocardial damage 1
Risk stratification should be performed based on clinical, electrocardiographic, and biochemical data 2

The European Society of Cardiology recommends aspirin 75-150 mg daily for high-risk patients with non-ST elevation acute coronary syndromes 2
The European Society of Cardiology recommends clopidogrel for high-risk patients with non-ST elevation acute coronary syndromes 2
The European Society of Cardiology recommends low molecular weight heparin (LMWH) such as enoxaparin or unfractionated heparin for high-risk patients with non-ST elevation acute coronary syndromes 2
High-risk features include recurrent ischemia, elevated troponin levels, hemodynamic instability, major arrhythmias, and diabetes mellitus 1

In resource-constrained settings, clopidogrel and enoxaparin remain cornerstone therapies for acute coronary syndromes, according to the American Heart Association 4

During the initial observation period, specific attention should be given to recurrence of chest pain, with ECG recording during symptoms, as recommended by the European Society of Cardiology 2
Signs of hemodynamic instability should be carefully noted and treated, as recommended by the European Society of Cardiology 2

Bleeding risk must be balanced against antithrombotic benefit, particularly in elderly patients or those with renal impairment, according to the European Society of Cardiology 5
Patients with ST-elevation myocardial infarction have different management protocols and may require immediate reperfusion therapy, as recommended by the European Society of Cardiology 2